Royal Bank Of Canada Reaffirms “Outperform” Rating for Oxford Biomedica (LON:OXB)

Oxford Biomedica (LON:OXB)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Digital Look reports. They presently have a GBX 900 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 106.66% from the stock’s current price.

Several other analysts have also recently commented on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 595 price target on shares of Oxford Biomedica in a report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Oxford Biomedica currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 580.85.

Oxford Biomedica Price Performance

Shares of OXB opened at GBX 435.49 on Tuesday. The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 162.16. The stock’s 50 day moving average is GBX 566.92 and its two-hundred day moving average is GBX 606.44. Oxford Biomedica has a twelve month low of GBX 427 and a twelve month high of GBX 952. The firm has a market capitalization of £527.10 million, a PE ratio of -16.18 and a beta of 1.10.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.